A dual role for NRP1 in VEGF- and ECM-driven angiogenesis during pathological angiogenesis may also explain why anti-VEGF and anti-NRP1 treatments have an additive effect in reducing tumour growth (Pan et al., 2007a). This evidence concerns the gene VEGFA and neoplasm.